Last updated: July 5, 2026
Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc. (1:14-cv-00121): Litigation Summary, Patent Claims, and Case Outcome Analysis
A complaint filed in 2014 by Forest Laboratories Inc. against Teva Pharmaceuticals USA Inc. underlies case number 1:14-cv-00121. The case is associated with branded vs. generic patent and regulatory exclusivity positioning typical of Hatch-Waxman disputes for central nervous system products, but the record required to produce a complete, accurate litigation summary for this specific docket (asserted patents, asserted counts, claim construction, settlement terms, and final judgment) is not available in the information provided.
What patents were asserted in Forest v. Teva 1:14-cv-00121?
No asserted-patent list (publication/application numbers, patent family member numbers, or specific claims) is included in the provided input.
Which asserted patent numbers and claims were at issue?
Not available from the provided information.
Who were the named plaintiffs and defendants for each side?
Not available beyond the party names in the prompt.
What happened procedurally in Forest v. Teva 1:14-cv-00121 (motions, stays, Markman)?
A procedural timeline requires docket-specific entries (complaint filing, answer, motion to dismiss, claim construction schedule, preliminary injunction motion, stipulations, and any appellate activity). Those entries are not present in the provided input.
Was there a preliminary injunction or temporary restraining order?
Not available from the provided information.
Was the case stayed pending FDA resolution or PTO proceedings?
Not available from the provided information.
Did the parties settle Forest v. Teva 1:14-cv-00121, and what were the settlement terms?
Settlement outcome and terms (early entry, licensed launch, payment-for-delay structure, covenant-not-to-sue scope, or tablet strength limitations) are not provided.
Was there a consent judgment, stipulation of dismissal, or dismissal without prejudice?
Not available from the provided information.
What was the final judgment or disposition for 1:14-cv-00121?
To summarize outcome, the record must identify the final dispositive order (e.g., summary judgment of noninfringement/invalidity, dismissal for lack of justiciability, or judgment after trial). No disposition details are included.
How did the court rule on infringement and validity (claim construction, § 271, § 282)?
A claims-and-elements analysis depends on:
- claim construction orders (Markman)
- infringement contentions and product mappings
- validity challenges (written description, enablement, obviousness, indefiniteness, and prosecution history)
None of these are included in the provided input.
Which legal standards were applied (e.g., obviousness KSR, indefiniteness Nautilus)?
Not available from the provided information.
What does the Orange Book status imply for Forest v. Teva 1:14-cv-00121?
Orange Book tie-in requires:
- the referenced listed drug (RLD)
- the ANDA number(s)
- the Orange Book listed patents and expiration dates
- the specific certifications (Paragraph I/II/III/IV) tied to the litigation
No Orange Book identifiers are provided.
Which ANDA and which Paragraph IV certifications triggered the litigation?
Not available from the provided information.
When did exclusivity and patent protections expire relative to the litigation (timing analysis)?
A timing analysis needs:
- earliest patent expiration
- exclusivity end dates (e.g., 5-year new chemical entity, 3-year new clinical investigation, 7-year orphan where applicable)
- any pediatric exclusivity extension
No dates are provided.
When is the first possible generic launch date under Hatch-Waxman?
Not available from the provided information.
What generic entry risks existed for Teva after Forest v. Teva 1:14-cv-00121?
Risk depends on the final outcome (especially whether key patents were found not infringed, invalid, or unenforceable) and any settlement entry date. No final outcome or settlement entry terms are included.
What biosimilar risk framework applies (if relevant)?
Not applicable unless the drug is biologic, which cannot be confirmed from the provided input.
How strong is the patent estate underlying this dispute (patent strength analysis)?
Patent strength analysis requires the asserted patent family, remaining lifespan, prosecution history, and any prior PTAB district-court outcomes. None are available.
Were there parallel PTO challenges (IPR/CBM) or reexams?
Not available from the provided information.
Which companies and products are competitive with Forest’s branded therapy in this litigation?
A competitive landscape requires identification of:
- the branded product
- Teva’s ANDA product and strengths
- other Paragraph IV challengers and settlements
None of these are stated in the provided input.
What revenue exposure and market share stakes were implicated?
Revenue exposure requires at minimum:
- branded annual sales around the filing year
- Teva’s competitive positioning and expected launch timing
No commercial figures are provided.
Key Takeaways
- The provided information identifies only the case caption and docket number (Forest Laboratories Inc. v. Teva Pharmaceuticals USA Inc., 1:14-cv-00121).
- A litigation summary that is accurate at the professional level requires docket-specific details (asserted patents, procedural posture, claim construction, dispositive rulings, and any settlement/judgment terms). Those details are not included in the provided input.
- No Orange Book, ANDA, Paragraph IV certification, exclusivity, or expiration-date mapping is available from the provided information.
FAQs
- What is the docket scope of 1:14-cv-00121 (district, judge, and assigned magistrate) for Forest v. Teva?
- Which FDA ANDA(s) and Orange Book RLD(s) correspond to Forest v. Teva 1:14-cv-00121?
- Were any asserted patents found invalid or not infringed in Forest v. Teva 1:14-cv-00121?
- If there was a settlement, what was the agreed generic entry date or launch “carve-out” scope?
- Were there any appeal outcomes or Federal Circuit activity tied to this docket?
References
(No sources were provided in the prompt.)
